In this substudy, immune biomarkers (PD-L1 expression on immune cells and tumor cells, intratumoral CD8, stromal TILs) and germinal BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel. The gene discussed is CD274; the disease is neoplasm.